Nature Communications (Dec 2021)

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

  • Georgia Zoumpoulidou,
  • Carlos Alvarez-Mendoza,
  • Caterina Mancusi,
  • Ritika-Mahmuda Ahmed,
  • Milly Denman,
  • Christopher D. Steele,
  • Maxime Tarabichi,
  • Errin Roy,
  • Lauren R. Davies,
  • Jiten Manji,
  • Camilla Cristalli,
  • Katia Scotlandi,
  • Nischalan Pillay,
  • Sandra J. Strauss,
  • Sibylle Mittnacht

DOI
https://doi.org/10.1038/s41467-021-27291-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

RB1 mutations are seen in 40-60% of sporadic osteosarcoma. Here, the authors demonstrate a selective sensitivity to PARP inhibitors in RB1-mutated osteosarcoma-derived cell lines that is not associated with canonical signatures indicative of a homologous recombination defect.